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Abstract: Although the detrimental effect upon psychological well-being of receiving a diagnosis of, or treatment for, 
cancer has been demonstrated across many different types of cancer, three recent reviews of the psychological health of 
prostate cancer patients have produced contradictory conclusions. In order to elucidate the reasons for these apparent different 
conclusions, each of these reviews is described, with principal methods and ﬁ  ndings summarised. Actual data, methodology 
used to select/reject research studies for inclusion in reviews, plus the validity of strict methodological culling of some 
research studies are discussed. Several extra studies and commentaries are also described, and a resolution of the apparent 
contradictory review conclusions is offered.
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Introduction
Receiving a diagnosis of cancer has been linked with a reduction in psychological well-being, Quality 
of Life, interpersonal relationships and optimism [1,2]. There are also data indicating that cancer patients 
who are anxious or depressed have poorer treatment outcomes, perhaps via lower compliance with 
medication [3], highlighting the need to address psychological functioning as an integral aspect of 
overall cancer treatment protocols. In support of this viewpoint, Greenberg [4: p. 1036] stated that 
“Inadequate treatment of major depressive disorders in this day and age is substandard oncology 
treatment”, a sentiment echoed in Australia by the NH&MRC Clinical Practice Guidelines for the 
Psychosocial Care of Adults with Cancer [5].
However, prior to administration of treatments aimed at alleviating the psychological sequelae of 
receiving a diagnosis of, and treatment for, cancer, the reliable identiﬁ  cation of the incidence of 
psychological distress needs to be determined. Although this has been reported for several cancer patient 
groups (e.g. breast cancer [6]), there has been some debate as to the existence of elevated psychologi-
cal distress among prostate cancer patients (PCa), with one review paper arguing that there was no real 
difference between the psychological distress of prostate cancer patients and their peers [7], but two 
other reviews claiming that the data from many studies indicate the presence of elevated anxiety and 
depression, plus lowered Quality of Life, among prostate cancer patients compared to their non-patient 
peers [8,9]. In order to resolve this apparent contradiction, the present paper examined the ﬁ  ndings from 
those three major reviews of the previous research which investigated the presence of psychological 
distress among PCa patients. Each of these reviews will be described below, with some comments upon 
their methodologies, ﬁ  ndings and conclusions. From that examination, overall ﬁ  ndings regarding the 
presence (or not) of elevated psychological distress among prostate cancer patients will be discussed 
and the aforementioned disagreement between the three reviews will be resolved.
While there have been many research reports on the issue of psychological distress among prostate 
cancer patients, plus the three reviews mentioned above and described below, there has been no recent 
overall summary of the ﬁ  eld to date, leaving the issue open to debate. Thus, this paper extends the previous 
literature by bringing together the previous major reviews and synthesizing their ﬁ  ndings. The present 
structure and style of ‘reviewing the reviews’ was chosen instead of an alternate methodology (e.g. meta-
analysis) because the process of gathering individual studies and reviewing them (as in the previous 564
Sharpley
Clinical Medicine: Oncology 2008:2
three reviews) has not produced a clear outcome to 
the questions of whether or not prostate cancer 
patients have higher levels of psychological distress 
than their peers. A further review of the original 
literature was considered not to be required at this 
juncture because performing another similar review 
might simply add to the disagreement shown by those 
three papers without advancing understanding of the 
overall literature to date and thus resolving the appar-
ent disagreement between those previous reviews.
Methods
The construct “psychological distress” was opera-
tionalised by reference to the nomenclature com-
monly used in the DSM-IV-TR [10] for “anxiety” 
and “depression” as representing the most common 
and researched indices of unhappiness of a psy-
chological nature. In addition, and because they 
may be used as indicators of the relative absence 
of psychological distress, the global terms “psy-
chological health” and “Quality of Life” were used 
to indicate the alternative “healthy” aspects of 
psychological status. “Quality of life” has been 
widely used in the health literature and may relate 
to a range of patient factors, including mental well-
being, physical status and emotional health as 
assessed by the patient [11].
From a search of Pub Med, PsychInfo, Google 
Scholar to February 2008, using the descriptors 
“prostate cancer”, “depression”, “anxiety”, “psycho-
logical health” and “Quality of Life”, plus follow-up 
hand searches, three reviews of the literature were 
identiﬁ  ed. Each of these three reviews was examined 
in terms of the articles they described, tabulations of 
data, measures of psychological distress used in the 
literature and conclusions drawn by the reviews. 
Each review was therefore “re-reviewed” by an 
examination of the original reports which had been 
reviewed and any discrepancies between the original 
data reported in the literature and the tabulations, 
descriptions or conclusions drawn by the three lit-
erature reviews were noted. On these bases, critical 
evaluations of the three literature were compiled and 
are presented below.
Results
Review 1: Bennet and Badger (2005)
Taken chronologically, Bennett and Badger [8] 
conducted the first comprehensive review of 
psychological distress among PCa patients from 
studies reported between 1988 and 2004. Those 
authors identiﬁ  ed 38 studies (27 of which were 
descriptive and 11 that used experimental or quasi-
experimental designs) from 39 published articles; 
12 studies had samples of PCa patients that were 
less than 50 in number, eight studies reported on 
samples of between 50 and 100 PCA patients and 
18 papers had samples of more than 100 PCa 
patients. Bennett and Badger focussed their review 
upon the incidence of depression among PCa men 
and noted that the Proﬁ  le of Mood States was the 
most frequently used measure of depression, fol-
lowed by the Hospital Anxiety and Depression 
Scale, the Beck Depression Inventory and the Cen-
ter for Epidemiological Studies-Depression scale.
Bennett and Badger organised their review 
across ﬁ  ve categories of depression incidence: 
those studies which reported on the prevalence and 
correlates of depression or other mood disorders 
(n = 9), papers that included depression in studies 
of fatigue and/or pain (4), studies of Quality of Life 
(QoL) and depression (12), the comparative inci-
dence of depression among PCA patients and their 
partners (4), and intervention studies which used 
mood as the principal dependant variable (9). It is 
of note that, although Bennett and Badger criticised 
some studies on methodological grounds, they still 
included them in their review on the basis that these 
studies contributed valuable information to the 
discussion despite the presence of some method-
ological shortcomings. However, they did indicate 
that issues needing to be addressed were: lack of 
uniformity among measures used to tap depression, 
assessment of mood (via the POMS) rather than 
depression per se, low representation of some 
ethnic and social-cultural subgroups within the 
society where the largest number of research stud-
ies were conducted (U.S.A.); and that these short-
comings limited the generalisability of the overall 
conclusions from their review to the wider popula-
tion of PCa patients. Bearing all these points in 
mind, Bennett and Badger nevertheless drew the 
conclusion that PCa patients experienced depressed 
mood at levels “higher than those reported for older 
men in the general population” (p. 554). Major risk 
factors for depressed mood were advanced PCa, 
prominent symptomatology and side effects from 
treatment, plus a prior history of depression. PCa 
patients in pain were also more likely to suffer 
depressed mood, whereas being married, receiving 
strong social support, being optimistic and having 565
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greater physical functioning were buffers against 
depressed mood in the samples studied. Of major 
import for the development of effective treatment 
options for PCa patients, Bennett and Badger noted 
that “the state of the science for supportive care 
interventions aimed toward men with prostate cancer 
is limited” (p. 554), thus emphasising the comments 
made by Greenberg (above) and the Guidelines of 
the NH&MRC and other similar national bodies that 
support provision of psychosocial care for all cancer 
patients as part of basic treatment protocols. This 
point is particularly relevant to the discussion of 
whether PCA patients actually do experience 
psychological distress at elevated frequencies 
compared to their non-PCa peers.
Review 2: Katz (2007)
The second major review of PCa patients’ psycho-
logical well-being was reported by Katz [9], who 
reviewed studies of PCa and Quality of Life (QoL) 
from 1999 to 2005, a briefer period than that tapped 
by Bennett and Badger, but also including more 
recent data. Overall, Katz examined 68 reports of 
QoL among PCA patients, and speciﬁ  cally evalu-
ated the effects of treatment modality (surgery, 
radiation therapy, cryosurgery) and also the effects 
of advanced PCa upon QoL. Katz’s conclusion 
mirrored that reported by Bennett and Badger: 
“Quality of Life is decreased in both the short and 
long terms for men with prostate cancer” (p. 302). 
However, one difference between the data reviewed 
by Bennett and Badger and that which Katz 
reviewed was the choice of the principal dependant 
variable. As mentioned above, Bennett and Badger 
included studies that used measures of mood 
(including depression) and QoL, whereas Katz 
restricted her review to QoL studies exclusively. 
Despite this different database, the conclusions 
drawn from these two reviews of PCa patients’ 
mood and QoL were congruent across these differ-
ent dependant variables and thus form a signiﬁ  cant 
statement regarding the psychological state of PCa 
patients.
It should, however, be noted that the use of QoL 
as an indicator of psychological distress may be 
ﬂ  awed because QoL does not assess the accepted 
symptomatology of psychological maladjustment. 
Chen [12] commented that QoL measures are 
designed to assess the patient’s perception of the 
effects of symptoms upon daily role function and 
may/may not include the psychological impact of 
those symptoms. Thus, QoL measures are not 
designed to act as screening instruments for anxiety 
or depression and are not validated on agreed 
criteria for any disorder, leading to “much disagree-
ment and confusion” about the exact meaning of 
QoL, with “researchers often using the same term 
(Quality of Life) to mean very different things” 
[12: p. 2695]. This means that the exact nature of 
QoL data is open to conjecture because of a “lack 
of standard criteria” [13, p. 626]. In terms of the 
implications of QoL data for intervention, Whelan 
et al. [14] noted that “Quality of life data are 
difﬁ  cult for clinicians to interpret” because they 
do not relate to clinical symptoms (p. 6937). Thus, 
it could be argued that the value of QoL data in 
determining the psychological health of PCa 
patients (and their need for additional treatment) 
is limited. This does not invalidate Katz’s review 
but does restrict the generalisability of her ﬁ  ndings 
to the speciﬁ  c issue of PCa patients’ psychological 
distress levels compared to their non-PCa 
counterparts.
By contrast, Nordin et al. [15] commented that, 
when investigating psychological distress and 
adjustment problems in cancer populations, 
“anxiety and depression are the most prevalent” 
indices to be assessed (p. 376). Both anxiety and 
depression are clearly deﬁ  ned in the ICD and 
DSM nomenclature and both are of major clinical 
signiﬁ  cance to patients and patient care. Thus, the 
reviews by Bennett and Badger and Katz which 
respectively focused on depressed mood and QoL 
of PCa patients may be viewed as being limited 
in demonstrating that this patient group is similar 
to other cancer patients in experiencing increased 
levels of psychological distress While mood and 
QoL are of value when investigating the general 
mental states of participants, they are also some-
what distanced from the key diagnostic criteria 
of anxiety and depression [10] that constitute 
mental illnesses in themselves (and thereby 
represent a major treatment challenge for clini-
cians who deal with PCa patients). Therefore, it 
may be that measuring the presence of symptoms 
of anxiety and depression directly via ICD- or 
DSM-based instruments or procedures could be 
more informative than using patients’ reﬂ  ections 
upon their mood or level of functioning and how 
these make them feel. On this basis, the focusing 
of research reviews upon those studies which 
apply valid and reliable measures of anxiety and 
depression to PCa patients is probably necessary 566
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to adequately address the issue of PCa patients’ 
psychological distress.
Review 3: Bloch et al. (2007)
The third major review of PCa patients’ psycho-
logical distress is also of value because it adopted a 
different approach to literature selection from that 
followed by Bennett and Badger and Katz. Bloch 
et al. [7] examined studies on the psychological 
effects of PCa that were reported between 1988 and 
June, 2006, noting that that “Few of the … investi-
gations have enlisted large samples or controls” 
(p. 3), leading those authors to exclude studies that 
were “methodologically inadequate” (p. 545). 
Applying these criteria, Bloch et al. found just three 
methodologically acceptable cross-sectional studies, 
plus two longitudinal studies of PCa patients’ psy-
chological distress and concluded from these ﬁ  ve 
studies that there were “few differences in levels of 
psychological distress” (p. 11) between men with 
and without PCa on the basis of “studies with rea-
sonably sized and unbiased samples with appropri-
ate designs, including adequate descriptions of 
instruments used” (p. 2). Because of its relatively 
different conclusions to those from Bennett and 
Badger and Katz, it is worth examining the proce-
dures and ﬁ  ndings of the Bloch et al. review in some 
greater detail to determine the validity of those 
conclusions vis-à-vis those of Bennett and Badger 
and Katz (even though those reviews were not 
speciﬁ  cally focussed upon psychological distress as 
deﬁ  ned in the DSM or ICD terms). As a ﬁ  rst step in 
that process, it is of relevance to examine the three 
cross-sectional and two longitudinal studies upon 
which Bloch et al. based their conclusion (Bacon 
et al. [16], Clark et al. [17], Helgason et al. [18], 
Nordin et al. [15] and Visser et al. [19]).
Bacon et al. [15] reported that PCa patients had 
signiﬁ  cantly worse scores on 7 out of 10 QoL 
subscales than controls but not on the mental 
subscale. Although the samples were restricted to 
a particular occupational group (i.e. health profes-
sionals) and thus results are limited in their gener-
alisability to the population of PCa patients, data 
do indicate that these PCa patients were experienc-
ing a signiﬁ  cantly lower overall quality of life than 
non-PCa men. Similarly, the widespread negative 
attitudes reported by PCa patients in Clark et al.’s 
[17] study were highlighted by those authors, who 
also commented on the unreliability of focussing 
upon the lack of differences between PCa patients 
and controls in global measures of health status. 
Helgason et al. [18] described their PCa sample as 
“significantly more likely to be distressed” 
(p. 1418) than non-PCa men due to decreases in 
sexual functioning. These three studies constituted 
what Bloch et al. described as those which “stand 
out since the samples are adequate and compared 
with controls” (p. 2), but they do not support Bloch 
et al.’s conclusion that “Men with PCa do not 
appear to experience marked impairment of 
adjustment” (p. 12). In addition, none of the three 
cross-sectional studies accepted by Bloch et al. as 
methodologically satisfactory actually used valid 
and reliable measures of depression or anxiety. 
Instead, these three papers used QoL, patient 
“attitudes” and “distress” as their DVs. While these 
data are valuable in describing the emotional states 
of the PCa patients examined, they do not assess 
anxiety or depression as deﬁ  ned in ICD or DSM 
terms.
Of the two longitudinal studies of psychological 
adjustment among PCa patients that met Bloch 
et al.’s methodological criteria for inclusion, 
Nordin et al. [15], collected HADS data from 
118 PCa patients close in time to their diagnosis 
and then again from 99 of these patients six months 
later. Data were also collected from breast, colorec-
tal and gastric cancer patients. Unfortunately, the 
HADS data reported were the group means for PCa 
and other patient groups rather than the percent 
who reached the cutoff score indicating an anxiety 
or depression disorder. Thus, it is not possible to 
determine the incidence of clinically depressed or 
anxious PCa patients at either diagnosis or six 
months later. Visser et al. [19], used a QoL instru-
ment as well as a shortened version of the Proﬁ  le 
of Mood States (POMS). Although the shorter 
POMS has a depression subscale, scores on the 
latter were not reported.
Thus, the data from the three cross-sectional 
and two longitudinal studies referred to by Bloch 
et al. as indicating a lack of difference in the psy-
chological distress of PCA patients versus their 
non-PC a peers may be of limited value because 
four of those studies used QoL as the main DV 
rather than measures of clinical anxiety or depres-
sion and also because the single study which did 
use a standardised measure of anxiety and depres-
sion (the HADS) did not report incidence data for 
the PCa sample which reached clinical levels of 
anxiety or depression. In addition, there were, in 
fact, several key datum which indicated that PCa 567
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patients were less happy with their health than 
non-PCa peers.
By contrast, of the three cross-sectional papers 
that focussed upon depressive symptoms and 
which were rejected by Bloch et al. on the basis of 
methodological weaknesses (Heim and Oei [20], 
Stone et al. [21], Balderson and Towell [22]), Heim 
and Oei [20] reported that 32% of their sample of 
PCa patients met the criteria for a clinical diagnosis 
of depression on the BDI, many times more than 
the 3% or less reported in national surveys of the 
older male population in Australia, where Heim 
and Oei collected their data. Stone et al.’s [21] data 
were not directly relevant to this discussion because 
PCa patients’ combined anxiety-depression mean 
scores (from the HADS) were not reported 
separately to other cancer patient groups, but 
Balderson and Towell [22] found 38% of their PCa 
sample met the criteria for combined anxiety-
depression on the HADS, well above the norms 
for this age group.
Discussion
These three reviews demonstrate some uncertainty 
on the issue of PCa patients’ psychological distress. 
As well as reporting two different conclusions, 
each of these reviews adopted a different stand on 
selection of studies to be reviewed. Bennett and 
Badger [8] included all 39 studies of depression 
among PCa patients that they identiﬁ  ed via elec-
tronic search and concluded that, while PCa 
patients were, on balance, more distressed than 
their non-PCa peers, the predominant measures 
used were focussed upon mood rather than ICD- or 
DSM-based anxiety or depression; Katz [9] 
restricted her review to those studies which used 
QoL as the principal dependant variable rather than 
psychological disorders, again including all studies 
regardless of methodological weaknesses and also 
concluding that PCa patients had relatively poorer 
QoL than non-PCa men. By contrast, Bloch et al. 
[7] excluded studies on the basis of strict method-
ological criteria and concluded (on the basis of 
those few studies which remained after exclusion) 
that there were no signiﬁ  cant differences in the 
psychological distress levels of PCa patients and 
their non-PCa peers.
As well as presenting contradictory conclusions, 
the three reviews described above raise several 
issues for further examination, principally those 
of: choice of DV and measures, selection of control 
groups or reference to normative data for purposes 
of comparison, the effects of research design vari-
ables upon validity of data reported and sample 
size. While the soundness of research methodology 
is undeniably an important aspect of selection of 
which studies to include in literature reviews, those 
methodological criteria need to be carefully con-
sidered before implementation. Specifically, 
although (as argued by Bloch et al.) cross-sectional 
‘snapshots’ do not provide data on the persistence 
of symptoms, they do tell us if there is a discrep-
ancy between the scores of a certain sample on a 
selected variable at a point in time when they are 
compared to another group or set of norms . While 
it would be valuable to know the features of depres-
sion and anxiety over time among PCa patients, 
the lack of such longitudinal knowledge does not 
preclude clinicians recognising that such distress 
exists and that it can hinder treatment and be det-
rimental to patient health and well-being. So, 
although a temporal “map” of psychosocial distress 
across all periods of PCa diagnosis, treatment and 
recovery is clearly of value (and such data have 
been reported [23,24]), simple snapshots are not 
worthless—they indicate whether this population 
ever experiences psychosocial distress that war-
rants intervention.
A major methodological aspect of cross-
sectional and longitudinal studies is the presence 
of control groups, which Bloch et al. described as 
“crucial” (p. 12). However, this is not necessarily 
the case in research which involves psychometric 
testing, where the accepted procedure is to refer to 
established norms when comparing the scores of 
a selected sample. For example, data from the 
Australian National Survey of Mental Health and 
Well-Being [25] showed that anxiety and depres-
sion decline with age [26], and that the prevalence 
of anxiety and depression among men aged 55 to 
64 was 6% and 3% respectively, dropping to 3.5% 
and 1.0% after age 65 [27]. Data collected from 
a sample of Australian PCa patients (at any time 
after their diagnosis) may be proﬁ  tably compared 
with these norms when drawing conclusions about 
the effects of PCa upon patients, thus obviating the 
need for another ‘control’ group. Similarly, the 
issue of adequate sample size is open to some 
further interpretation than simply classifying stud-
ies as methodologically insufﬁ  cient because they 
use samples that are smaller than might be ideal. 
Power analysis may be proﬁ  table where the null 
hypothesis has been accepted, but ad hoc rejection 568
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of studies simply on the basis of sample size is 
probably overly-hasty. It was pointed out some 
time ago by Glass, McGaw and Smith [28] that the 
sample size of a particular study can be coded and 
evaluated for consideration when reviewing the 
overall ﬁ  ndings of literature reviews.
However, the major issue that arises from these 
three reviews is the choice of dependant variables 
used to assess the incidence of psychological 
distress. There is a clear difference between QoL 
and a psychiatric diagnosis of anxiety or depression 
and there are different issues being investigated 
when QoL is the DV than when ICD- or DSM-based 
diagnoses of anxiety and depression are made. We 
would agree with Nordin et al. [15] that it is the 
latter which command the first attention of 
researchers who investigate the psychological 
effects of PCa upon patients and the consequent 
need for intervention to address those mental health 
problems which may interfere with treatment 
compliance and adversely affect patients and their 
relationships.
Although on a purely numerical basis (i.e. 2 out 
of 3), the overall conclusion that could be drawn 
from the above evaluation of the three literature 
reviews would that there is evidence of elevated 
levels of unhappiness or depressed mood (includ-
ing QoL) among PCa patients compared to their 
non-PCA peers, this is not clear-cut, leaving the 
question open to some conjecture. While conduct-
ing another comprehensive literature review so 
soon after these three might bear relatively poor 
cost-beneﬁ  t outcomes, an alternative way to further 
examine these ﬁ  ndings is to set up a test of the null 
hypothesis (i.e. that there is no signiﬁ  cantly differ-
ent level of psychological distress among PCa 
patients compared to non-PCa men of similar age). 
This test may be conducted by randomly selecting 
a discrete number of studies which examined the 
research question using sound methodology and 
valid and reliable instrumentation. Although it is 
impossible to determine the exact number of such 
studies needed to conclusively and ﬁ  nally reject 
the null hypothesis in question herein, the advice 
of Kazdin [29] that systematic replication (i.e. 
“repetition of the experiment by systematically 
allowing features to vary” (p. 489)) may be fol-
lowed by selecting studies which showed some 
variability in terms of national origin of sample, 
instruments used, settings where data were 
collected and time collected (i.e. from initial biopsy 
to post-treatment).
Resolving the contradiction: Testing 
the null hypothesis
On this basis, we gathered a small random selection 
of recent studies to act as a vehicle for testing the 
claim that there are no significant differences 
between the levels of psychological distress of PCa 
patients and their non-PCa peers. These studies are 
presented as a representative sample of the wider 
recent literature but are not intended to constitute 
a comprehensive review. Rather, they are described 
to offer a brief indicator of the kind of research 
into the psychological distress experienced by PCa 
patients that has been published recently and, as 
such, to pose a test of the null hypothesis that there 
is no signiﬁ  cant difference between the level of 
psychological distress of PCA patients and their 
non-PCA peers.
From a Google Scholar search in March, 2008, 
with the descriptors “prostate cancer, anxiety, 
depression” for the period 1997 to 2007, we iden-
tiﬁ  ed six studies which reported upon the incidence 
of clinically signiﬁ  cant anxiety and/or depression 
among PCa patients. As well as the criteria for 
systematic replication mentioned above, these 
studies were selected on the bases of (a) having 
used well-recognised measures of anxiety and/or 
depression, (b) having sufﬁ  ciently large samples 
to allow generalisability to the population, (c) being 
from national sources where norms of the incidence 
of anxiety and depression were available in some 
form, and (d) using a recognized research design 
that was generally free from major sources of 
experimental invalidity. To adequately represent 
the national source of most studies of PCA, four 
studies that collected data from men in the U.S.A. 
were identiﬁ  ed. Second, to provide a cross-cultural 
comparison, one study from a similar society 
(Australia) and one study from a dissimilar society 
(Japan) were also selected. Each of these six stud-
ies is brieﬂ  y described below, followed by a sum-
mary of these data and their implications for 
consideration of the incidence of psychological 
distress among PCa patients.
Studies selected
Dale, Hemmerrich and Meltzer [30] assessed 
anxiety among 178 prostate cancer patients with 
an average age of 63.1 years who were recruited 
at the Chicago University at the time of biopsy 
(i.e. prior to treatment but with an awareness 
that PCa might become their formal diagnosis). 569
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Those authors reported that the mean HADS-A 
score was 3.70 (with 7 being the cutoff for presence 
of clinically signiﬁ  cant anxiety) but that 18% of 
their sample had scores above this cutoff level, 
indicating the presence of “at least mild clinical 
anxiety” (p. 496).
Pirl, Gebrielle, Siegel, Goode and Smith [31] 
examined the results of Structured Clinical Inter-
views for DSM-IV (SCID) and BDI scores of 45 men 
aged between 51 and 83 years (M = 69.4 years) who 
had been diagnosed with PCa for an average of 
6.4 years and who were patients at the Massachusetts 
General Hospital. According to the SCID, 12.8% of 
the sample qualiﬁ  ed for “major depressive disorder” 
(p. 521), and 13.3% of the sample met the criteria 
for mild to moderate depression on the BDI.
Monahan, Champion, Rawl, Giesler, Given, 
Given et al. [32] assessed depression among 105 PCa 
patients aged from 42 to 80 years (M = 64 years) 
who were “newly treated” (p. 401) for PCa via 
radical prostatectomy, radiation therapy or brachy-
therapy in Indiana, Michigan and Louisville. The 
instrument used to assess depression was the Center 
for Epidemiologic Studies-Depression Scale 
(CES-D), which identiﬁ  ed 16% of the sample as 
having clinical depression.
Roth, Kornblith, Batel-Copel, Peabody, Scher 
and Holland [33] used the HADS to assess anxiety 
and depression in 121 PCa patients from New York 
who had an average age of 71 years (range = 52 to 
88 years) and who had received their PCa diagnosis 
a median of 4 years previously. Thirty-two percent 
of the sample scored above the HADS anxiety 
cutoff and 15.2% scored above the HADS depres-
sion cutoff. In addition, 17 of these patients were 
assessed by a psychiatrist and eight met the crite-
ria for a DSM-IV disorder.
Sharpley and Christie [34] assessed anxiety and 
depression among 185 Australian PCa patients 
aged from 54 to 81 years (M = 69.2 years) who 
had received their diagnosis an average of 1 year, 
10 months previously. Patients were asked to 
complete the Zung Self-Rating Anxiety Scale 
(SAS) and the Zung Self-Rating Depression Scale 
(SDS). The incidence of clinical anxiety disorder 
and depressive disorder on the SAS and SDS were 
11.8% and 13.3% respectively.
In keeping with Kazdin’s [29] recommendations 
regarding systematic replication, the data reported 
in these ﬁ  ve papers were collected from men from 
the U.S.A. or Australia, two similar societies and 
nations for which data are available regarding the 
national incidence of anxiety and depression. One 
study assessed anxiety alone, two examined 
depression alone and two collected data on both 
anxiety and depression. In addition, several differ-
ent instruments and procedures were used to collect 
these data, including the HADS, BDI, DSM-IV 
Structured Interviews, CES-D, and Zung’s SAS 
and SDS, all of which possess satisfactory validity 
and reliability. With samples of between 45 and 
185 PCa patients, none of these reports could rea-
sonably be described as so small as to invalidate 
the data reported therein. Finally, data were 
collected from immediately before formal diagno-
sis [30], soon after diagnosis [32] and at two, four 
and six years after diagnosis [34,33,31]. Thus, if 
there were consistent ﬁ  ndings across (a) nations, 
(b) samples within nations, (c) instruments and 
procedures and (d) time after (or before) diagnosis, 
the requirements of systematic replication might 
be seen to have been observed. Further, if these 
ﬁ  ndings were indicative of levels of anxiety and 
depression that were elevated above the reported 
national norms, then it might be reasonable to draw 
some conclusions regarding the effects of PCa 
upon patients’ psychological well-being among the 
wider population.
By reference to the DSM-IV-TR [10], the 
general community 1-year prevalence rate for Gen-
eralised Anxiety Disorder is about 3% and the point 
prevalence rate for Major Depressive Disorder in 
between 2% and 3% for men. While these data 
apply to the whole of lifespan, Form [35] reviewed 
27 studies of age differences in depression, 10 of 
the prevalence of anxiety disorders and 13 of dis-
tress and concluded that “age is associated with less 
anxiety and depression” (p. 20). These APA [10] 
rates are most relevant to the U.S.A. but ﬁ  gures 
from Australia [26,27] mentioned earlier in 
this paper state that the prevalence of anxiety is 
between 6% and 3.5% for men aged 55+, and 
for depression the prevalence rate is between 3% 
and 1%. Using these norms for the two relevant 
populations (i.e. U.S.A., Australia) obviates the 
need for control groups and shows that the rates 
reported in the ﬁ  ve studies mentioned above are well 
above those that might be expected for comparably-
aged men in the U.S.A. or Australia. While the direct 
comparisons with the APA data are only able to be 
made where the DSM-IV-Structured Interview 
process has been used (i.e. as by Pirl, Gebrielle, 
Siegel, Goode and Smith [31]), those data indicated 
that 12.8% of their sample met the criteria for Major 570
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Depressive Disorder, more than four times that 
which might be expected. The data collected on 
Australian men with PCa [34] indicated that 11.8% 
were clinically anxious, nearly double the popula-
tion rate of 6%; the incidence of depression (16%) 
in that sample was over ﬁ  ve times the 3% rate for 
depression expected from people of the same age 
range in Australia [26]. Thus, there is consistency of 
outcome across the data from U.S.A. and Australia, 
plus consistency across those studies conducted 
only with U.S.A. participants, thus providing some 
within-population replication. Further, although the 
instruments and procedures varied, the ﬁ  ndings are 
generally in agreement across them. That is, 
although the BDI focuses upon mostly cognitive 
symptoms, the HADS excludes those physical 
symptoms which may be associated with disease, 
the SAS and SDS include items that tap the range 
of symptoms which comprise DSM-based criteria, 
and the SCID directly assesses the presence of those 
DSM criteria, the levels of anxiety and depression 
encountered within these samples and with these 
instruments are uniform in being elevated well 
above the norms for the age groups sampled. 
Finally, there is consistency in the ﬁ  nding of ele-
vated anxiety and depression among PCa samples 
regardless of how soon they were assessed after (or 
before) formal diagnosis. Thus, it appears reason-
able to conclude that there is sufﬁ  cient evidence of 
anxiety and depression among PCa patients in these 
ﬁ  ve studies to conclude that they experience ele-
vated psychological distress compared to their 
non-PCa peers.
As mentioned above, all of these ﬁ  ve studies were 
from Western populations and so a further study 
conducted on Japanese men was also examined. By 
adding “Japan” to the search criteria described above 
(i.e. “prostate cancer, anxiety, depression”) the 
report by Namiki, Saito, Tochigi, Numata, Ioritani 
and Arai [36] was located. Those authors investi-
gated the presence of psychological distress among 
340 Japanese PCa patients and used some QoL 
measures and the HADS-A and HADS-D, plus a 
combined measure of these two subscales called 
HADS-T. Patients were classiﬁ  ed as anxiety or 
depression “cases” based upon a previous study of 
Japanese PCa patients’ normative data [37]. On this 
basis, 114 (33.5%) of the sample were found to be 
anxiety and depression “cases.” Although national 
norms of the incidence of anxiety and depression in 
Japan were not obtained, it is highly unlikely that 
they would show a third of men in the age group 
studied to be clinically depressed or anxious. Thus, 
these cross-cultural data reinforce the conclusions 
drawn from the USA and Australian data reported 
in the previous ﬁ  ve recent studies and provide a 
systematic replication of the examination of the 
levels of psychological distress among PCa patients 
compared with non-PCa peers. While there is no 
upper limit to the number of systematic replications 
needed to provide complete generalisability [38], 
the consistent ﬁ  ndings reported by all six studies 
across settings, nationalities, societies, instruments, 
stage of PCa development and treatment, present 
substantial evidence to refute the null hypothesis 
that there are no signiﬁ  cant differences between the 
levels of psychological distress of PCa patients 
compared to their non-PCA peers.
Commentaries
In addition to these six reports on anxiety and 
depression among PCa patients, ﬁ  ve other recent 
papers were brieﬂ  y considered. Mehnert, Lehmann, 
Schulte and Koch [39] found that 53% of 197 PCa 
patients experienced “prevalent” nervousness, wor-
ries, fears and sadness. Although these authors did 
not report formal DSM-IV-TR disorders, they raised 
the important point that many (in this case over half) 
of their sample of PCa patients were signiﬁ  cantly 
psychologically distressed by their diagnosis and 
treatment. When added to Sellick and Crooks’ [40] 
ﬁ  ndings that 19% to 43% of cancer patients expe-
rienced high levels of depressive symptoms and 6% 
to 15% met the strict criteria for a clinical diagnosis 
of major depression; that depression has been shown 
to adversely affect treatment efﬁ  cacy [41]); and that 
the major unmet need reported by cancer patients 
is in regard to their psychological distress [42], it 
appears clear that at least some PCa patients (many 
more than would be expected among their non-PCa 
peers) suffer psychological distress worthy of 
clinical attention and treatment, just as do all other 
cancer patient groups so far investigated.
Although there were no conclusive data pre-
sented by any of the three reviews which supported 
the null hypothesis, it is worthwhile to note Katz’s 
[9] comment that, in regard to the stress of PCa 
diagnosis and treatment, “Men may not complain 
about these symptoms when interacting with 
healthcare professionals” because they wish to 
focus upon a “ ‘survival at all costs’ attitude, and 
they may accept any and all side effects without 
complaint.” (p. 306). This comment is worthy of 571
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consideration because it points to a potentially 
confounding variable in studies of PCa patients’ 
psychological distress that may lead to Type II 
errors when evaluating the incidence of clinical 
distress among this patient group.
Conclusion
There is no doubt that attention to issues of meth-
odology, research design and some of the other 
criteria commonly used to asses the validity of 
research studies can promote scientiﬁ  c reﬂ  ection. 
However, there are sufﬁ  cient data reported so far, 
plus clinical observations aplenty, to assume that 
receiving a diagnosis or treatment for PCa is highly 
likely to be a signiﬁ  cantly distressing occasion for 
a substantial proportion of these men. It appears 
from the data reviewed herein (both from the previ-
ous reviews and from the later selection of six 
studies) that PCa patients experience levels of 
anxiety and depression that are elevated above those 
of their fellows, with a greater incidence of clini-
cally signiﬁ  cant anxiety and depression overall than 
men without PCa. Just as for other cancer patients, 
this is a most challenging and sometimes psycho-
logically distressing experience for many men and 
(also as for other cancer patients), receiving such a 
diagnosis may lead to anxiety and depression which 
adversely inﬂ  uence these men’s relationships with 
others [1,2] and adherence to treatment [3], thus 
further complicating the provision of treatment and 
potentially reducing its effectiveness.
Although not the primary focus of the present 
paper, some comment may be made regarding 
recommendations for clinicians when they are 
delivering the diagnostic information which has 
been shown above to lead to psychological 
distress. First, there are some data which suggest 
that anxiety and depression among cancer patients 
may be minimized by adequate explanations of 
diagnostic information and treatment options 
[43,44]. Other data indicate that an individually-
focussed approach to each patient’s informational 
needs, which might include a tour of the treatment 
facility or online access to the patient’s own 
records, can lead to reduced psychological distress 
[45]. Second, it must be accepted that receiving a 
diagnosis of cancer will be distressing for most 
people and therefore this reaction should be seen 
as part of the overall process which will, according 
to previous studies, reduce over time [46]. While 
they may (and should) be aware of the particular 
informational needs of their patients, including 
the fact that a few patients will prefer not to receive 
any information at all [47], clinicians need not set 
a goal of a distress-free consultation when 
delivering a diagnosis of prostate cancer. As has 
been argued at length elsewhere [48,49], the ‘nor-
mal’ response to experiencing aversive events is 
to withdraw, prepare for the worst outcome and 
reﬂ  ect upon mortality, and this is most likely to 
occur to many prostate cancer patients. The provi-
sion of supportive psychological therapies which 
focus upon the therapist-patient rapport [50] by 
associated health staff, plus monitoring of patient 
emotional well-being may be effective avenues of 
clinician response to the psychological distress 
which they are likely to encounter in their prostate 
cancer patients.
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